高盛公司将拜耳评级上调至买进；目标价33欧元，即上涨31%。 ...

美国FDA批准拜耳前列腺癌药物达洛鲁胺 智通财经6月4日电，拜耳公司当地时间6月3日宣布，美国食品和药物管理局（FDA）已批准其口服雄激 素受体抑制剂Nubeqa™（达洛鲁胺）与雄激素剥夺疗法（ADT）联用，用于转移性去势抵抗性前列腺 癌。 ...

拜耳(Bayer)表示，其药物Nubeqa已获得美国食品药品管理局(Food and Drug Administration)的批准；该 药物用于治疗患有特定类型前列腺癌的患者。这家德国生命科学公司表示，此番批准是基于一项3期试 验的积极结果。相关试验结果显示，在接受Nubeqa联合另一种疗法治疗的患者中，发生影像学进展或 死亡的风险降低了46%。 ...

Bayer (BAYRY) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the label extension for Eylea 8 mg (aflibercept) in the EU.This extension will enable longer treatment intervals, up to six months, for two major retinal conditions, neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME), pending approval by the European Commission.A decision is anticipated in the coming ...

日前，拜耳集团发布声明表示，为确保其作物科学部门的全球竞争力，正在重组位于德国的作物保护生 产和研发业务。拜耳将在2028年底后停止在法兰克福工厂的生产活动，并在同年底前简化多马根工厂的 生产。 拜耳作物科学部门相关人士表示，拜耳仍然致力于德国，但急需采取措施来应对产能严重过剩，以及与 亚洲仿制药制造商的价格竞争，以维持在德国的生产设施，并继续为客户生产具有竞争力的产品。 拜耳法兰克福工厂主要从事除草剂活性成分和制剂的生产，以及除草剂的研发。该公司表示，计划剥离 该工厂部分生产活动，剩余部分将转移到多马根和克那普萨克地区(Knapsack)工厂，或整合到欧洲制剂 生产网络。 5月13日公布的一季度业绩显示，拜耳作物科学事业部销售额下降了3.3%，至75.80亿欧元;不计特殊项 目的息税折旧摊销前利润下降了10.2%，至25.57亿欧元。 拜耳表示，未来的重点将更多地放在战略性创新技术和产品上。作物保护产品活性成分的创新至关重 要，未来十年，作物科学研发活动将推出几款重磅产品。 拜耳表示，蒙海姆工厂将更加专注于作物保护产品的研发。2023年8月，拜耳在蒙海姆开始建设一个用 于开发作物保护产品的设施。 拜耳补充道 ...

Bayer AG (BAYRY) announced that it has initiated a phase I study, which is evaluating its investigational highly selective GIRK4 inhibitor, BAY 3670549, for the treatment of patients with atrial fibrillation (AFib).The double-blind, placebo-controlled first-in-human dose escalation study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of BAY 3670549 in healthy participants.AFib is a common heart rhythm disorder that affects around 60 million people across the world. AFib is a notab ...

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- May marks Women’s Health Month, a timely reminder that while many women prioritize the health of others, their own well-being matters just as much. Recently, Dr. Yesmean Wahdan, Board-Certified OB/GYN and Medical Affairs Head for Women’s Health at Bayer, participated in a nationwide satellite media tour to share important advice for women of all ages. Women experience unique and evolving health milestones, and being proactive with annual checkups, including OB/GYN ...

A lot has happened since my last article about Bayer A.G. ( OTCPK:BAYZF , OTCPK:BAYRY ). The company’s stock price is trading near multi-year lows. And the company has recently published its earnings results , which haveA research analyst and a freelance writer looking for value investment opportunities. I have several years of investing experience. I am mostly interested in writing about bargain stocks of large companies. My interest is not limited to American companies but extends to firms operating in ot ...

智通财经5月16日电，媒体援引消息人士称，拜耳正准备一份计划，就密苏里州"农达"（Roundup）除 草剂的部分大规模诉讼达成和解，如果和解失败，拜耳还可能寻求让子公司孟山都（Monsanto）破产。 这家德国制药和生物技术集团已经支付了大约100亿美元来解决有关"农达"致癌的争议。 拜耳寻求就除草剂致癌案达成和解 并探讨让子公司孟山都破产 ...

Bayer AG BAYRY reported on Tuesday that the first quarter of 2025 net profit was 1.3 billion euros (around $1.45 billion), down from 2 billion euros a year ago.The company reported:Adjusted earnings of 65 cents, beating the consensus of 38 cents.Sales reached $14.45 billion (13.74 billion euros), beating the consensus of $13.39 billion.EBITDA before restructuring and litigation charges fell 7% year-on-year to 4 billion euros in the first quarter.Earnings were held back by the business performance in the Cro ...